Literature DB >> 9596120

Bronchial reactivity to cigarette smoke in smokers: repeatability, relationship to methacholine reactivity, smoking and atopy.

E J Jensen1, R Dahl, F Steffensen.   

Abstract

Bronchial reactivity to cigarette smoke (CBR) in a cross-section of 98 smokers has been investigated. All participants were subjects to skin-prick tests to common allergens, lung function measurements and bronchial challenges with methacholine and cigarette smoke. In 38 participants a rechallenge with cigarettes was performed 1 h after the first cigarette challenge. Lung function indices analysed were: forced expiratory volume in one second (FEV1); maximal expiratory flow at 75% of the forced vital capacity (MEF75%); and forced mid-expiratory flow between 25 and 75% of the forced vital capacity (FEF(25-75%)). All participants were tested for asthma and allergy, and were required to provide information regarding respiratory symptoms, first degree relatives with asthma and allergy and smoking habits. A substantial decrease was seen in all lung function indices after 12 cigarette-smoke inhalations, but only FEV1 was related to other variables. The maximal mean percentage fall in FEV1 was 10%, which was directly related to the number of inhalations (p<0.05). In multiple regression analyses the percentage fall in FEV1 was directly related to: FEV1/vital capacity (VC) (p<0.01); to the asthmatic/bronchitic status (p<0.05); and to the accumulated and standardized cigarette consumption (p<0.05). The percentage fall in FEV1 bore no relationship to methacholine bronchial reactivity, sex or age and had a continuous distribution. The repeat challenge showed a smaller fall in FEV1 compared to the first challenge after 12 cigarette smoke inhalations (p<0.05). The percentage fall in FEV1 correlated after the first and the repeat challenge (p<0.05). Repeatability of the challenge could not be determined in this study because of tachyphylaxis. Bronchial reactivity to cigarette smoke is a tobacco smoke-specific bronchial response. All participants responded and the response showed a continuous distribution. Bronchial reactivity to cigarette smoke may be of importance for symptoms and prognosis in chronic bronchitis and chronic obstructive pulmonary disease and should be studied in relation to the degree of accelerated lung function loss in smokers and other cigarette induced lung abnormalities.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9596120

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  6 in total

1.  Cross shift changes in lung function among bar and restaurant workers before and after implementation of a smoking ban.

Authors:  M Skogstad; K Kjaerheim; G Fladseth; M Gjølstad; H L Daae; R Olsen; P Molander; D G Ellingsen
Journal:  Occup Environ Med       Date:  2006-03-21       Impact factor: 4.402

Review 2.  Systematic review with meta-analysis of the epidemiological evidence relating smoking to COPD, chronic bronchitis and emphysema.

Authors:  Barbara A Forey; Alison J Thornton; Peter N Lee
Journal:  BMC Pulm Med       Date:  2011-06-14       Impact factor: 3.317

Review 3.  Methyl methacrylate and respiratory sensitization: a critical review.

Authors:  Jonathan Borak; Cheryl Fields; Larry S Andrews; Mark A Pemberton
Journal:  Crit Rev Toxicol       Date:  2011-03       Impact factor: 5.635

Review 4.  Impact of smoking on asthma therapy: a critical review of clinical evidence.

Authors:  Eric Livingston; Neil C Thomson; George W Chalmers
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 5.  Clinical implications of airway hyperresponsiveness in COPD.

Authors:  Nicola Scichilone; Salvatore Battaglia; Alba La Sala; Vincenzo Bellia
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2006

6.  Seasons can influence the results of the methacholine challenge test.

Authors:  Bruno Sposato; Marco Scalese; Andrea Pammolli; Raffaele Scala; Mario Naldi
Journal:  Ann Thorac Med       Date:  2012-04       Impact factor: 2.219

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.